Karyopharm Therapeutics | KPTI - Equity Capital And Reserves


Karyopharm Therapeutics reported $-265.65M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Abbott USD 52.06B 69M Mar/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Takeda JPY 7.56T 215.7B Jun/2026
Tectonic Therapeutic USD 230.42M 20.91M Mar/2026
TG Therapeutics USD 604.08M 20.95M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026